nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—PTGIR—pulmonary artery—systemic scleroderma	0.0548	0.154	CbGeAlD
Epoprostenol—CYP2C9—cardial valve—systemic scleroderma	0.0484	0.136	CbGeAlD
Epoprostenol—PTGIS—artery—systemic scleroderma	0.0354	0.0997	CbGeAlD
Epoprostenol—P2RY12—artery—systemic scleroderma	0.0318	0.0898	CbGeAlD
Epoprostenol—PTGIS—endothelium—systemic scleroderma	0.0299	0.0842	CbGeAlD
Epoprostenol—PTGIS—blood vessel—systemic scleroderma	0.0275	0.0777	CbGeAlD
Epoprostenol—PTGIR—artery—systemic scleroderma	0.0203	0.0573	CbGeAlD
Epoprostenol—PTGIR—endothelium—systemic scleroderma	0.0172	0.0484	CbGeAlD
Epoprostenol—PTGIR—blood vessel—systemic scleroderma	0.0158	0.0446	CbGeAlD
Epoprostenol—PTGIS—connective tissue—systemic scleroderma	0.0141	0.0398	CbGeAlD
Epoprostenol—PTGIS—smooth muscle tissue—systemic scleroderma	0.0129	0.0364	CbGeAlD
Epoprostenol—PTGIS—tendon—systemic scleroderma	0.00971	0.0274	CbGeAlD
Epoprostenol—PTGIS—lung—systemic scleroderma	0.00852	0.024	CbGeAlD
Epoprostenol—PTGIR—connective tissue—systemic scleroderma	0.00811	0.0229	CbGeAlD
Epoprostenol—PTGIR—smooth muscle tissue—systemic scleroderma	0.00742	0.0209	CbGeAlD
Epoprostenol—PTGIR—digestive system—systemic scleroderma	0.00586	0.0165	CbGeAlD
Epoprostenol—PTGIR—lung—systemic scleroderma	0.00489	0.0138	CbGeAlD
Epoprostenol—CYP2C9—digestive system—systemic scleroderma	0.00209	0.0059	CbGeAlD
Epoprostenol—Headache—Mometasone—systemic scleroderma	0.00066	0.00102	CcSEcCtD
Epoprostenol—Tremor—Mycophenolate mofetil—systemic scleroderma	0.000659	0.00102	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000658	0.00102	CcSEcCtD
Epoprostenol—Insomnia—Mycophenolic acid—systemic scleroderma	0.000658	0.00102	CcSEcCtD
Epoprostenol—Fatigue—Leflunomide—systemic scleroderma	0.000657	0.00102	CcSEcCtD
Epoprostenol—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000655	0.00102	CcSEcCtD
Epoprostenol—Oedema—Lisinopril—systemic scleroderma	0.000655	0.00102	CcSEcCtD
Epoprostenol—Pruritus—Captopril—systemic scleroderma	0.000655	0.00101	CcSEcCtD
Epoprostenol—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000653	0.00101	CcSEcCtD
Epoprostenol—Pain—Leflunomide—systemic scleroderma	0.000652	0.00101	CcSEcCtD
Epoprostenol—Constipation—Leflunomide—systemic scleroderma	0.000652	0.00101	CcSEcCtD
Epoprostenol—Infection—Lisinopril—systemic scleroderma	0.000651	0.00101	CcSEcCtD
Epoprostenol—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.00065	0.00101	CcSEcCtD
Epoprostenol—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000648	0.001	CcSEcCtD
Epoprostenol—Somnolence—Mycophenolic acid—systemic scleroderma	0.000647	0.001	CcSEcCtD
Epoprostenol—Agitation—Mycophenolate mofetil—systemic scleroderma	0.000646	0.001	CcSEcCtD
Epoprostenol—Shock—Lisinopril—systemic scleroderma	0.000645	0.000999	CcSEcCtD
Epoprostenol—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000641	0.000994	CcSEcCtD
Epoprostenol—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.00064	0.000992	CcSEcCtD
Epoprostenol—Tachycardia—Lisinopril—systemic scleroderma	0.000639	0.000991	CcSEcCtD
Epoprostenol—Abdominal pain—Azathioprine—systemic scleroderma	0.000638	0.000989	CcSEcCtD
Epoprostenol—Body temperature increased—Azathioprine—systemic scleroderma	0.000638	0.000989	CcSEcCtD
Epoprostenol—Skin disorder—Lisinopril—systemic scleroderma	0.000636	0.000986	CcSEcCtD
Epoprostenol—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000633	0.000981	CcSEcCtD
Epoprostenol—Diarrhoea—Captopril—systemic scleroderma	0.000633	0.000981	CcSEcCtD
Epoprostenol—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000632	0.00098	CcSEcCtD
Epoprostenol—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000631	0.000977	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000628	0.000973	CcSEcCtD
Epoprostenol—Fatigue—Mycophenolic acid—systemic scleroderma	0.000627	0.000972	CcSEcCtD
Epoprostenol—Nausea—Mometasone—systemic scleroderma	0.000626	0.000969	CcSEcCtD
Epoprostenol—Anorexia—Lisinopril—systemic scleroderma	0.000624	0.000968	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000623	0.000966	CcSEcCtD
Epoprostenol—Constipation—Mycophenolic acid—systemic scleroderma	0.000622	0.000964	CcSEcCtD
Epoprostenol—Pain—Mycophenolic acid—systemic scleroderma	0.000622	0.000964	CcSEcCtD
Epoprostenol—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000622	0.000963	CcSEcCtD
Epoprostenol—Weight decreased—Prednisone—systemic scleroderma	0.000619	0.000959	CcSEcCtD
Epoprostenol—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000618	0.000958	CcSEcCtD
Epoprostenol—Cough—Mycophenolate mofetil—systemic scleroderma	0.000614	0.000951	CcSEcCtD
Epoprostenol—Hypotension—Lisinopril—systemic scleroderma	0.000612	0.000949	CcSEcCtD
Epoprostenol—Dizziness—Captopril—systemic scleroderma	0.000612	0.000948	CcSEcCtD
Epoprostenol—Depression—Prednisone—systemic scleroderma	0.000608	0.000943	CcSEcCtD
Epoprostenol—Urticaria—Leflunomide—systemic scleroderma	0.000606	0.000939	CcSEcCtD
Epoprostenol—Body temperature increased—Leflunomide—systemic scleroderma	0.000603	0.000934	CcSEcCtD
Epoprostenol—Abdominal pain—Leflunomide—systemic scleroderma	0.000603	0.000934	CcSEcCtD
Epoprostenol—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000601	0.000932	CcSEcCtD
Epoprostenol—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000599	0.000928	CcSEcCtD
Epoprostenol—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000599	0.000928	CcSEcCtD
Epoprostenol—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000599	0.000928	CcSEcCtD
Epoprostenol—Myocardial infarction—Prednisone—systemic scleroderma	0.000598	0.000927	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000597	0.000925	CcSEcCtD
Epoprostenol—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000597	0.000925	CcSEcCtD
Epoprostenol—Hypersensitivity—Azathioprine—systemic scleroderma	0.000595	0.000922	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000595	0.000922	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000595	0.000921	CcSEcCtD
Epoprostenol—Insomnia—Lisinopril—systemic scleroderma	0.000593	0.000918	CcSEcCtD
Epoprostenol—Paraesthesia—Lisinopril—systemic scleroderma	0.000588	0.000912	CcSEcCtD
Epoprostenol—Vomiting—Captopril—systemic scleroderma	0.000588	0.000911	CcSEcCtD
Epoprostenol—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000586	0.000907	CcSEcCtD
Epoprostenol—Dyspnoea—Lisinopril—systemic scleroderma	0.000584	0.000905	CcSEcCtD
Epoprostenol—Rash—Captopril—systemic scleroderma	0.000583	0.000904	CcSEcCtD
Epoprostenol—Dermatitis—Captopril—systemic scleroderma	0.000583	0.000903	CcSEcCtD
Epoprostenol—Somnolence—Lisinopril—systemic scleroderma	0.000582	0.000902	CcSEcCtD
Epoprostenol—Headache—Captopril—systemic scleroderma	0.00058	0.000898	CcSEcCtD
Epoprostenol—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000579	0.000897	CcSEcCtD
Epoprostenol—Dyspepsia—Lisinopril—systemic scleroderma	0.000577	0.000894	CcSEcCtD
Epoprostenol—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000575	0.000891	CcSEcCtD
Epoprostenol—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000575	0.000891	CcSEcCtD
Epoprostenol—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000574	0.000889	CcSEcCtD
Epoprostenol—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000574	0.000889	CcSEcCtD
Epoprostenol—Infection—Mycophenolate mofetil—systemic scleroderma	0.00057	0.000884	CcSEcCtD
Epoprostenol—Decreased appetite—Lisinopril—systemic scleroderma	0.00057	0.000882	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000566	0.000876	CcSEcCtD
Epoprostenol—Fatigue—Lisinopril—systemic scleroderma	0.000565	0.000875	CcSEcCtD
Epoprostenol—Shock—Mycophenolate mofetil—systemic scleroderma	0.000565	0.000875	CcSEcCtD
Epoprostenol—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000563	0.000872	CcSEcCtD
Epoprostenol—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000562	0.000871	CcSEcCtD
Epoprostenol—Hypersensitivity—Leflunomide—systemic scleroderma	0.000562	0.00087	CcSEcCtD
Epoprostenol—Pain—Lisinopril—systemic scleroderma	0.00056	0.000868	CcSEcCtD
Epoprostenol—Constipation—Lisinopril—systemic scleroderma	0.00056	0.000868	CcSEcCtD
Epoprostenol—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.00056	0.000868	CcSEcCtD
Epoprostenol—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000558	0.000864	CcSEcCtD
Epoprostenol—Bradycardia—Prednisone—systemic scleroderma	0.000558	0.000864	CcSEcCtD
Epoprostenol—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000555	0.00086	CcSEcCtD
Epoprostenol—Diarrhoea—Azathioprine—systemic scleroderma	0.000552	0.000856	CcSEcCtD
Epoprostenol—Haemoglobin—Prednisone—systemic scleroderma	0.00055	0.000853	CcSEcCtD
Epoprostenol—Nausea—Captopril—systemic scleroderma	0.000549	0.000851	CcSEcCtD
Epoprostenol—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000548	0.000849	CcSEcCtD
Epoprostenol—Haemorrhage—Prednisone—systemic scleroderma	0.000548	0.000849	CcSEcCtD
Epoprostenol—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000547	0.000848	CcSEcCtD
Epoprostenol—Asthenia—Leflunomide—systemic scleroderma	0.000547	0.000848	CcSEcCtD
Epoprostenol—Pancytopenia—Methotrexate—systemic scleroderma	0.000543	0.000841	CcSEcCtD
Epoprostenol—Pruritus—Leflunomide—systemic scleroderma	0.000539	0.000836	CcSEcCtD
Epoprostenol—Connective tissue disorder—Prednisone—systemic scleroderma	0.000538	0.000834	CcSEcCtD
Epoprostenol—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000536	0.000831	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000536	0.00083	CcSEcCtD
Epoprostenol—Dizziness—Azathioprine—systemic scleroderma	0.000534	0.000827	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000523	0.00081	CcSEcCtD
Epoprostenol—Asthenia—Mycophenolic acid—systemic scleroderma	0.000522	0.000809	CcSEcCtD
Epoprostenol—Diarrhoea—Leflunomide—systemic scleroderma	0.000522	0.000808	CcSEcCtD
Epoprostenol—Urticaria—Lisinopril—systemic scleroderma	0.00052	0.000806	CcSEcCtD
Epoprostenol—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000519	0.000804	CcSEcCtD
Epoprostenol—Body temperature increased—Lisinopril—systemic scleroderma	0.000518	0.000802	CcSEcCtD
Epoprostenol—Abdominal pain—Lisinopril—systemic scleroderma	0.000518	0.000802	CcSEcCtD
Epoprostenol—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000515	0.000799	CcSEcCtD
Epoprostenol—Pruritus—Mycophenolic acid—systemic scleroderma	0.000515	0.000797	CcSEcCtD
Epoprostenol—Vomiting—Azathioprine—systemic scleroderma	0.000513	0.000795	CcSEcCtD
Epoprostenol—Pneumonia—Methotrexate—systemic scleroderma	0.000513	0.000795	CcSEcCtD
Epoprostenol—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000512	0.000793	CcSEcCtD
Epoprostenol—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.00051	0.000791	CcSEcCtD
Epoprostenol—Infestation NOS—Methotrexate—systemic scleroderma	0.00051	0.00079	CcSEcCtD
Epoprostenol—Infestation—Methotrexate—systemic scleroderma	0.00051	0.00079	CcSEcCtD
Epoprostenol—Rash—Azathioprine—systemic scleroderma	0.000509	0.000789	CcSEcCtD
Epoprostenol—Dermatitis—Azathioprine—systemic scleroderma	0.000509	0.000788	CcSEcCtD
Epoprostenol—Depression—Methotrexate—systemic scleroderma	0.000508	0.000788	CcSEcCtD
Epoprostenol—Flushing—Prednisone—systemic scleroderma	0.000508	0.000788	CcSEcCtD
Epoprostenol—Headache—Azathioprine—systemic scleroderma	0.000506	0.000784	CcSEcCtD
Epoprostenol—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000505	0.000783	CcSEcCtD
Epoprostenol—Dizziness—Leflunomide—systemic scleroderma	0.000504	0.000781	CcSEcCtD
Epoprostenol—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000499	0.000773	CcSEcCtD
Epoprostenol—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000498	0.000771	CcSEcCtD
Epoprostenol—Angiopathy—Prednisone—systemic scleroderma	0.000497	0.00077	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000496	0.000768	CcSEcCtD
Epoprostenol—Pain—Mycophenolate mofetil—systemic scleroderma	0.000491	0.000761	CcSEcCtD
Epoprostenol—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000491	0.000761	CcSEcCtD
Epoprostenol—Sweating—Methotrexate—systemic scleroderma	0.000489	0.000757	CcSEcCtD
Epoprostenol—Haematuria—Methotrexate—systemic scleroderma	0.000486	0.000753	CcSEcCtD
Epoprostenol—Vomiting—Leflunomide—systemic scleroderma	0.000485	0.000751	CcSEcCtD
Epoprostenol—Hypersensitivity—Lisinopril—systemic scleroderma	0.000483	0.000748	CcSEcCtD
Epoprostenol—Dizziness—Mycophenolic acid—systemic scleroderma	0.000481	0.000745	CcSEcCtD
Epoprostenol—Epistaxis—Methotrexate—systemic scleroderma	0.000481	0.000745	CcSEcCtD
Epoprostenol—Rash—Leflunomide—systemic scleroderma	0.000481	0.000745	CcSEcCtD
Epoprostenol—Dermatitis—Leflunomide—systemic scleroderma	0.00048	0.000744	CcSEcCtD
Epoprostenol—Mental disorder—Prednisone—systemic scleroderma	0.00048	0.000743	CcSEcCtD
Epoprostenol—Nausea—Azathioprine—systemic scleroderma	0.00048	0.000743	CcSEcCtD
Epoprostenol—Headache—Leflunomide—systemic scleroderma	0.000478	0.00074	CcSEcCtD
Epoprostenol—Asthenia—Lisinopril—systemic scleroderma	0.00047	0.000728	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000469	0.000727	CcSEcCtD
Epoprostenol—Pruritus—Lisinopril—systemic scleroderma	0.000464	0.000718	CcSEcCtD
Epoprostenol—Vomiting—Mycophenolic acid—systemic scleroderma	0.000462	0.000717	CcSEcCtD
Epoprostenol—Haemoglobin—Methotrexate—systemic scleroderma	0.00046	0.000713	CcSEcCtD
Epoprostenol—Rash—Mycophenolic acid—systemic scleroderma	0.000459	0.000711	CcSEcCtD
Epoprostenol—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000458	0.00071	CcSEcCtD
Epoprostenol—Haemorrhage—Methotrexate—systemic scleroderma	0.000458	0.000709	CcSEcCtD
Epoprostenol—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000456	0.000707	CcSEcCtD
Epoprostenol—Headache—Mycophenolic acid—systemic scleroderma	0.000456	0.000706	CcSEcCtD
Epoprostenol—Pharyngitis—Methotrexate—systemic scleroderma	0.000454	0.000704	CcSEcCtD
Epoprostenol—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000454	0.000703	CcSEcCtD
Epoprostenol—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000454	0.000703	CcSEcCtD
Epoprostenol—Nausea—Leflunomide—systemic scleroderma	0.000453	0.000702	CcSEcCtD
Epoprostenol—Diarrhoea—Lisinopril—systemic scleroderma	0.000448	0.000695	CcSEcCtD
Epoprostenol—Anaemia—Prednisone—systemic scleroderma	0.000441	0.000683	CcSEcCtD
Epoprostenol—Agitation—Prednisone—systemic scleroderma	0.000438	0.000679	CcSEcCtD
Epoprostenol—Dizziness—Lisinopril—systemic scleroderma	0.000433	0.000671	CcSEcCtD
Epoprostenol—Nausea—Mycophenolic acid—systemic scleroderma	0.000432	0.000669	CcSEcCtD
Epoprostenol—Syncope—Prednisone—systemic scleroderma	0.000428	0.000662	CcSEcCtD
Epoprostenol—Cardiac disorder—Methotrexate—systemic scleroderma	0.000425	0.000658	CcSEcCtD
Epoprostenol—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000423	0.000655	CcSEcCtD
Epoprostenol—Loss of consciousness—Prednisone—systemic scleroderma	0.000419	0.000649	CcSEcCtD
Epoprostenol—Vomiting—Lisinopril—systemic scleroderma	0.000417	0.000645	CcSEcCtD
Epoprostenol—Angiopathy—Methotrexate—systemic scleroderma	0.000415	0.000643	CcSEcCtD
Epoprostenol—Rash—Lisinopril—systemic scleroderma	0.000413	0.00064	CcSEcCtD
Epoprostenol—Dermatitis—Lisinopril—systemic scleroderma	0.000413	0.000639	CcSEcCtD
Epoprostenol—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000413	0.000639	CcSEcCtD
Epoprostenol—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000412	0.000638	CcSEcCtD
Epoprostenol—Chills—Methotrexate—systemic scleroderma	0.000411	0.000636	CcSEcCtD
Epoprostenol—Headache—Lisinopril—systemic scleroderma	0.00041	0.000636	CcSEcCtD
Epoprostenol—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000406	0.000629	CcSEcCtD
Epoprostenol—Myalgia—Prednisone—systemic scleroderma	0.000406	0.000629	CcSEcCtD
Epoprostenol—Arthralgia—Prednisone—systemic scleroderma	0.000406	0.000629	CcSEcCtD
Epoprostenol—Anxiety—Prednisone—systemic scleroderma	0.000404	0.000627	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000403	0.000625	CcSEcCtD
Epoprostenol—Mental disorder—Methotrexate—systemic scleroderma	0.000401	0.000621	CcSEcCtD
Epoprostenol—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000393	0.000609	CcSEcCtD
Epoprostenol—Nausea—Lisinopril—systemic scleroderma	0.000389	0.000603	CcSEcCtD
Epoprostenol—Anaphylactic shock—Prednisone—systemic scleroderma	0.000389	0.000603	CcSEcCtD
Epoprostenol—Oedema—Prednisone—systemic scleroderma	0.000389	0.000603	CcSEcCtD
Epoprostenol—Infection—Prednisone—systemic scleroderma	0.000387	0.000599	CcSEcCtD
Epoprostenol—Back pain—Methotrexate—systemic scleroderma	0.000385	0.000597	CcSEcCtD
Epoprostenol—Shock—Prednisone—systemic scleroderma	0.000383	0.000593	CcSEcCtD
Epoprostenol—Nervous system disorder—Prednisone—systemic scleroderma	0.000382	0.000591	CcSEcCtD
Epoprostenol—Tachycardia—Prednisone—systemic scleroderma	0.00038	0.000588	CcSEcCtD
Epoprostenol—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.00038	0.000588	CcSEcCtD
Epoprostenol—Skin disorder—Prednisone—systemic scleroderma	0.000378	0.000586	CcSEcCtD
Epoprostenol—Hyperhidrosis—Prednisone—systemic scleroderma	0.000376	0.000583	CcSEcCtD
Epoprostenol—Anorexia—Prednisone—systemic scleroderma	0.000371	0.000575	CcSEcCtD
Epoprostenol—Anaemia—Methotrexate—systemic scleroderma	0.000368	0.000571	CcSEcCtD
Epoprostenol—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000365	0.000566	CcSEcCtD
Epoprostenol—Rash—Mycophenolate mofetil—systemic scleroderma	0.000362	0.000561	CcSEcCtD
Epoprostenol—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000362	0.00056	CcSEcCtD
Epoprostenol—Headache—Mycophenolate mofetil—systemic scleroderma	0.00036	0.000557	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000354	0.000549	CcSEcCtD
Epoprostenol—Insomnia—Prednisone—systemic scleroderma	0.000352	0.000545	CcSEcCtD
Epoprostenol—Paraesthesia—Prednisone—systemic scleroderma	0.000349	0.000541	CcSEcCtD
Epoprostenol—Cough—Methotrexate—systemic scleroderma	0.000348	0.000539	CcSEcCtD
Epoprostenol—Dyspepsia—Prednisone—systemic scleroderma	0.000343	0.000531	CcSEcCtD
Epoprostenol—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000341	0.000528	CcSEcCtD
Epoprostenol—Myalgia—Methotrexate—systemic scleroderma	0.000339	0.000526	CcSEcCtD
Epoprostenol—Chest pain—Methotrexate—systemic scleroderma	0.000339	0.000526	CcSEcCtD
Epoprostenol—Arthralgia—Methotrexate—systemic scleroderma	0.000339	0.000526	CcSEcCtD
Epoprostenol—Decreased appetite—Prednisone—systemic scleroderma	0.000338	0.000524	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000337	0.000522	CcSEcCtD
Epoprostenol—Fatigue—Prednisone—systemic scleroderma	0.000335	0.00052	CcSEcCtD
Epoprostenol—Constipation—Prednisone—systemic scleroderma	0.000333	0.000516	CcSEcCtD
Epoprostenol—Confusional state—Methotrexate—systemic scleroderma	0.000328	0.000508	CcSEcCtD
Epoprostenol—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000325	0.000504	CcSEcCtD
Epoprostenol—Infection—Methotrexate—systemic scleroderma	0.000323	0.000501	CcSEcCtD
Epoprostenol—Nervous system disorder—Methotrexate—systemic scleroderma	0.000319	0.000494	CcSEcCtD
Epoprostenol—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000318	0.000493	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000318	0.000493	CcSEcCtD
Epoprostenol—Skin disorder—Methotrexate—systemic scleroderma	0.000316	0.000489	CcSEcCtD
Epoprostenol—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000314	0.000487	CcSEcCtD
Epoprostenol—Anorexia—Methotrexate—systemic scleroderma	0.00031	0.00048	CcSEcCtD
Epoprostenol—Urticaria—Prednisone—systemic scleroderma	0.000309	0.000479	CcSEcCtD
Epoprostenol—Abdominal pain—Prednisone—systemic scleroderma	0.000308	0.000477	CcSEcCtD
Epoprostenol—Body temperature increased—Prednisone—systemic scleroderma	0.000308	0.000477	CcSEcCtD
Epoprostenol—Hypotension—Methotrexate—systemic scleroderma	0.000304	0.000471	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000296	0.000459	CcSEcCtD
Epoprostenol—Insomnia—Methotrexate—systemic scleroderma	0.000294	0.000456	CcSEcCtD
Epoprostenol—Paraesthesia—Methotrexate—systemic scleroderma	0.000292	0.000452	CcSEcCtD
Epoprostenol—Dyspnoea—Methotrexate—systemic scleroderma	0.00029	0.000449	CcSEcCtD
Epoprostenol—Somnolence—Methotrexate—systemic scleroderma	0.000289	0.000448	CcSEcCtD
Epoprostenol—Hypersensitivity—Prednisone—systemic scleroderma	0.000287	0.000444	CcSEcCtD
Epoprostenol—Dyspepsia—Methotrexate—systemic scleroderma	0.000286	0.000444	CcSEcCtD
Epoprostenol—Decreased appetite—Methotrexate—systemic scleroderma	0.000283	0.000438	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000281	0.000435	CcSEcCtD
Epoprostenol—Fatigue—Methotrexate—systemic scleroderma	0.00028	0.000434	CcSEcCtD
Epoprostenol—Asthenia—Prednisone—systemic scleroderma	0.000279	0.000433	CcSEcCtD
Epoprostenol—Pain—Methotrexate—systemic scleroderma	0.000278	0.000431	CcSEcCtD
Epoprostenol—Pruritus—Prednisone—systemic scleroderma	0.000275	0.000427	CcSEcCtD
Epoprostenol—Diarrhoea—Prednisone—systemic scleroderma	0.000266	0.000413	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000266	0.000412	CcSEcCtD
Epoprostenol—Urticaria—Methotrexate—systemic scleroderma	0.000258	0.0004	CcSEcCtD
Epoprostenol—Dizziness—Prednisone—systemic scleroderma	0.000257	0.000399	CcSEcCtD
Epoprostenol—Abdominal pain—Methotrexate—systemic scleroderma	0.000257	0.000398	CcSEcCtD
Epoprostenol—Body temperature increased—Methotrexate—systemic scleroderma	0.000257	0.000398	CcSEcCtD
Epoprostenol—Vomiting—Prednisone—systemic scleroderma	0.000247	0.000383	CcSEcCtD
Epoprostenol—Rash—Prednisone—systemic scleroderma	0.000245	0.00038	CcSEcCtD
Epoprostenol—Dermatitis—Prednisone—systemic scleroderma	0.000245	0.00038	CcSEcCtD
Epoprostenol—Headache—Prednisone—systemic scleroderma	0.000244	0.000378	CcSEcCtD
Epoprostenol—Hypersensitivity—Methotrexate—systemic scleroderma	0.00024	0.000371	CcSEcCtD
Epoprostenol—Asthenia—Methotrexate—systemic scleroderma	0.000233	0.000362	CcSEcCtD
Epoprostenol—Nausea—Prednisone—systemic scleroderma	0.000231	0.000358	CcSEcCtD
Epoprostenol—Pruritus—Methotrexate—systemic scleroderma	0.00023	0.000356	CcSEcCtD
Epoprostenol—Diarrhoea—Methotrexate—systemic scleroderma	0.000222	0.000345	CcSEcCtD
Epoprostenol—Dizziness—Methotrexate—systemic scleroderma	0.000215	0.000333	CcSEcCtD
Epoprostenol—Vomiting—Methotrexate—systemic scleroderma	0.000207	0.00032	CcSEcCtD
Epoprostenol—Rash—Methotrexate—systemic scleroderma	0.000205	0.000318	CcSEcCtD
Epoprostenol—Dermatitis—Methotrexate—systemic scleroderma	0.000205	0.000317	CcSEcCtD
Epoprostenol—Headache—Methotrexate—systemic scleroderma	0.000204	0.000316	CcSEcCtD
Epoprostenol—Nausea—Methotrexate—systemic scleroderma	0.000193	0.000299	CcSEcCtD
